Hidradenitis suppurativa
Saved in:
| Title: | Hidradenitis suppurativa |
|---|---|
| Authors: | Ring, Hans Christian, Riis, Peter Theut, Rasmussen, Mads, Bertelsen, Trine, Dufour, Nathalie, Schøsler, Louise, Bjørn, Marie Nørgård, Svendsen, Morten Bue, Simonsen, Stine, Kofoed, Kristian, Thomsen, Simon Francis, Jemec, Gregor Be, Saunte, Ditte Marie Lindhardt |
| Source: | Ring, H C, Riis, P T, Rasmussen, M, Bertelsen, T, Dufour, N, Schøsler, L, Bjørn, M N, Svendsen, M B, Simonsen, S, Kofoed, K, Thomsen, S F, Jemec, G B & Saunte, D M L 2025, 'Hidrosadenitis suppurativa', Ugeskrift for Laeger, bind 187, nr. 14, V09240657, s. 1-8. https://doi.org/10.61409/V09240657 Ring, H C, Riis, P T, Rasmussen, M, Bertelsen, T, Dufour, N, Schøsler, L, Bjørn, M N, Svendsen, M B, Simonsen, S, Kofoed, K, Thomsen, S F, Jemec, G B & Saunte, D M L 2025, 'Hidrosadenitis suppurativa', Ugeskrift for Læger, bind 187, nr. 14. https://doi.org/10.61409/V09240657 |
| Publisher Information: | Danish Medical Association, 2025. |
| Publication Year: | 2025 |
| Subject Terms: | Metabolic Syndrome, Hidradenitis Suppurativa/diagnosis, Hidradenitis Suppurativa/drug therapy, Anti-Inflammatory Agents, Humans, Biological Products/therapeutic use, Anti-Inflammatory Agents/therapeutic use, Metabolic Syndrome/complications, Hidradenitis Suppurativa |
| Description: | This review covers the recent literature on various treatment strategies, associated comorbidities and diagnosis of hidradenitis suppurativa (HS). HS is a chronic inflammatory skin condition that can pose a considerable challenge to treat. HS is associated with various comorbidities, such as metabolic syndrome and psychiatric disorders. Data demonstrates a significant diagnostic delay, which may contribute to the long preceding treatment history with multiple drug classes and treatment series before initiation of biologic therapy. Although adalimumab, secukinumab, and bimekizumab are the only approved biologics by EMA for moderate to severe HS, many promising biologics are currently being investigated for moderate to severe HS. |
| Document Type: | Article |
| File Description: | application/pdf |
| ISSN: | 1603-6824 0041-5782 |
| DOI: | 10.61409/v09240657 |
| Access URL: | https://pubmed.ncbi.nlm.nih.gov/40171910 |
| Rights: | CC BY NC ND |
| Accession Number: | edsair.doi.dedup.....6fa6c111ba7f4c3327b81d1dde13ed9c |
| Database: | OpenAIRE |
Nájsť tento článok vo Web of Science | Abstract: | This review covers the recent literature on various treatment strategies, associated comorbidities and diagnosis of hidradenitis suppurativa (HS). HS is a chronic inflammatory skin condition that can pose a considerable challenge to treat. HS is associated with various comorbidities, such as metabolic syndrome and psychiatric disorders. Data demonstrates a significant diagnostic delay, which may contribute to the long preceding treatment history with multiple drug classes and treatment series before initiation of biologic therapy. Although adalimumab, secukinumab, and bimekizumab are the only approved biologics by EMA for moderate to severe HS, many promising biologics are currently being investigated for moderate to severe HS. |
|---|---|
| ISSN: | 16036824 00415782 |
| DOI: | 10.61409/v09240657 |